Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-09-30 was 0.00 shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-03-31 was 0.00 shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-12-31 was -81.96K shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 43.00 shares, a 99.98% decline from fiscal 2014.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2014 was 185.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-09 | -81.96K shares derived: sum of 4 quarters · filed 2017-03-09 |
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | -81.96K shares derived: sum of 4 quarters · filed 2017-03-09 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-09 | -33.96K shares derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-12-31 | -81.96K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | 43.00 shares 10-K · filed 2017-03-09 |
| 2015-09-30 | 0.00 shares 10-Q · filed 2015-11-09 | |
| 2015-06-30 | 48.00K shares 10-Q · filed 2015-08-10 | |
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-09 | |
| 2014-12-31 | 185.00K shares 10-K · filed 2016-03-15 | |
| 2014-06-30 | 10.00K shares 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |